A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2002
11/12/2002	US6479637 Hemoglobin-haptoglobin complexes
11/12/2002	US6479636 Extracting the sugarcane to obtai cane pression juice; cleaning pression sugarcane juice to remove particulate matter; adjusting; transmitting through membrane separation system to produce apt fractions
11/12/2002	US6479635 Receptor activator of NF-κB
11/12/2002	US6479634 IL-B30 proteins
11/12/2002	US6479633 Chemokine alpha 2
11/12/2002	US6479632 Tumor necrosis factor inhibitory protein and its purification
11/12/2002	US6479630 Human purinergic P2U receptor
11/12/2002	US6479627 Aqueous preparation of lactoferrin having improved stability
11/12/2002	US6479626 Poly zinc finger proteins with improved linkers
11/12/2002	US6479545 Formulation for menopausal women
11/12/2002	US6479540 Compositions of tocol-soluble therapeutics
11/12/2002	US6479492 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/12/2002	US6479481 Administering an effective dose of a cns tumor-inhibiting methylol transfer agent such as: taurolidine, taurultam or a mixture thereof.
11/12/2002	US6479471 Novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit n-acetylated .alpha.-linked acidic dipeptidase (naaladase) enzyme activity to treat prostate diseases
11/12/2002	US6479465 Methods of treating colitis using STAT-4 anti-sense oligonucleotides
11/12/2002	US6479464 Polypeptide comprising of the following 29 amino acid composition: 6g's, 2f's, 2l's, 1w, 4r's, 2e's, 2n's, 3k's, 1t, 1s, 1a, 1y, 1m, 1c, and 1i, and additional cationic residues to provide a net number of positive charges of at least 8
11/12/2002	US6479460 Pseudopeptidic osteogenic growth polypeptide
11/12/2002	US6479459 Cytokine designated lerk-5
11/12/2002	US6479458 Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
11/12/2002	US6479457 Polypeptide comprising at least one effective ionogenic amine ionically bound to polymer; drug delivery systems for the controlled release of pharmaceutical polypeptides
11/12/2002	US6479286 Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells
11/12/2002	US6479274 DNA molecules encoding human HELA2 or testisin serine proteinases
11/12/2002	US6479270 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
11/12/2002	US6479269 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/12/2002	US6479266 IKK-α proteins nucleic acids and methods
11/12/2002	US6479265 Catalytic antibodies which hydrolyze primary amides and methods for eliciting and use of such antibodies
11/12/2002	US6479261 Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells
11/12/2002	US6479256 Lectomedin materials and methods
11/12/2002	US6479254 Polypeptide for use in treatment of lymphadenopathy, autoimmune disease and graft versus host disease; antitumor agents
11/12/2002	US6479253 Serine protease inhibitor nucleic acid molecules and uses thereof
11/12/2002	US6479250 Eck receptor ligands
11/12/2002	US6479245 Monoclonal antibody which is specific for activated coagulation factor VII, and its use
11/12/2002	US6479243 Method for generating libraries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
11/12/2002	US6479078 Substantially crystalline form of melagatran
11/12/2002	US6479063 Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
11/12/2002	US6479060 Elegant hydrogenated castor oil ointments
11/12/2002	US6479055 Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
11/12/2002	US6479052 Spray delivery of cells
11/12/2002	US6479049 Methods and compositions for the dry powder formulation of interferons
11/12/2002	US6479047 Lymphotactin as an adjuvant
11/12/2002	US6479032 Calcitonin receptor binding reagents
11/12/2002	US6478967 Removal of contaminants from biological products
11/12/2002	CA2271781C Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
11/12/2002	CA2220684C Process for controlling sialylation of proteins produced by mammalian cell culture
11/12/2002	CA2202633C Peptide mixture and products thereof
11/12/2002	CA2169635C Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
11/12/2002	CA2138647C Radioactively-labeled somatostatin-derived peptides for imaging and therapeutic uses
11/12/2002	CA2101227C Chlorophyll and bacteriochlorophyll derivatives and pharmaceutical compositions containing them
11/12/2002	CA2088917C Therapeutic ribozyme compositions
11/12/2002	CA2077102C Antibiotic ge 2270 factor c2a
11/12/2002	CA2055963C Chimeric fibroblast growth factor
11/12/2002	CA2055948C Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria
11/12/2002	CA2009533C Novel cyclosporin galenic forms
11/11/2002	CA2347350A1 Control of cell growth by altering cell membrane potentials
11/11/2002	CA2347335A1 Ngf for the prevention of demyelination in the nervous system
11/07/2002	WO2002088664A2 Control of compactability through crystallization
11/07/2002	WO2002088393A1 Antisense modulation of tumor necrosis factor receptor 2 expression
11/07/2002	WO2002088392A1 Antisense modulation of gu protein expression
11/07/2002	WO2002088391A1 Antisense modulation of bifunctional apoptosis regulator expression
11/07/2002	WO2002088384A1 Screening method
11/07/2002	WO2002088380A2 Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
11/07/2002	WO2002088367A1 Production of the lantibiotic cinnamycin with genes isolated from streptomyces cinnamoneus
11/07/2002	WO2002088366A1 Von willebrand factor (vwf)-cleaving enzyme
11/07/2002	WO2002088363A2 Regulation of novel human prolyl 4-hydroxylases
11/07/2002	WO2002088358A2 Human fibroblast growth factor-related compositions
11/07/2002	WO2002088356A1 Novel g protein-coupled receptor protein and dna thereof
11/07/2002	WO2002088354A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
11/07/2002	WO2002088341A2 P450 proteins
11/07/2002	WO2002088334A1 Chimeric immunoreceptor useful in treating human cancers
11/07/2002	WO2002088322A2 Cell adhesion and extracellular matrix proteins
11/07/2002	WO2002088320A2 rAAV-VECTORED RIBOZYME COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DISEASES
11/07/2002	WO2002088317A2 Fusion molecules and methods for treatment of immune diseases
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088314A2 Ovary-specific genes and proteins
11/07/2002	WO2002088312A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
11/07/2002	WO2002088304A2 Compositions and methods for suppressing immune responses
11/07/2002	WO2002088303A2 Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
11/07/2002	WO2002088184A1 A molecular marker
11/07/2002	WO2002088183A2 G-protein coupled receptor
11/07/2002	WO2002088181A2 Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
11/07/2002	WO2002088180A2 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
11/07/2002	WO2002088178A2 Antigens of group b streptococcus and corresponding dna fragments
11/07/2002	WO2002088172A2 Pentapeptide compounds and uses related thereto
11/07/2002	WO2002088163A1 Antisense modulation of interferon gamma receptor 2 expression
11/07/2002	WO2002088162A1 Antisense modulation of interferon gamma receptor 1 expression
11/07/2002	WO2002087631A1 Gastrin-receptor-avid peptide conjugates
11/07/2002	WO2002087625A1 Composite oncolytic herpes virus vectors
11/07/2002	WO2002087621A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
11/07/2002	WO2002087616A1 Preventives for postoperative recurrence of premenopausal breast cancer
11/07/2002	WO2002087613A1 Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
11/07/2002	WO2002087610A1 Medical device
11/07/2002	WO2002087609A1 Identification of a cell surface receptor for papillomaviruses
11/07/2002	WO2002087607A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
11/07/2002	WO2002087606A2 Modulators of the hypocretin system and methods of screening therefor
11/07/2002	WO2002087605A2 Modified fvii in treatment of ards
11/07/2002	WO2002087604A2 Preparations containing a combination of vitamin e and afamin
11/07/2002	WO2002087600A1 Use of phyllanthus constituents for treating or preventing infections caused by hepatit
11/07/2002	WO2002087599A1 Compositions for treating animal diseases and syndromes
11/07/2002	WO2002087597A1 Oral delivery of macromolecules
11/07/2002	WO2002087593A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method

1 ... 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 ... 3163